Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01078636 · ClinicalTrials.gov registry record
Alzheimer's Disease Neuroimaging Initiative Grand Opportunity
A clinical trial of Mild Cognitive Impairment and Alzheimers Disease, sponsored by Alzheimer's Disease Cooperative Study (ADCS).
- Completed
- Registry status
- 342
- Enrollment target
- 20
- Study locations
NCT01078636 is a study of Mild Cognitive Impairment and Alzheimers Disease that has completed, run by Alzheimer's Disease Cooperative Study (ADCS). The registered enrollment target is 342 participants, below the 1,269-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT01078636, a study of Mild Cognitive Impairment and Alzheimers Disease, has completed, sponsored by Alzheimer's Disease Cooperative Study (ADCS).
- COMPLETED
- Registry status
- 342 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to build upon the information obtained in the original Alzheimer's Disease Neuroimaging Initiative (ADNI1), to examine how brain imaging technology can be used with other tests to measure the progression of mild cognitive impairment (MCI) and early Alzheimer's disease (AD). ADNI-GO seeks to define and characterize the mildest symptomatic phase of AD, referred to in this study as early amnestic MCI (EMCI). This information will aid in the early detection of AD, and in measuring the effectiveness of treatments in future clinical trials.
Conditions Studied
Study Locations (20)
California
- University of California, Irvine - Irvine
- University of California, Irvine - BIC - Irvine
- University of Southern California - Los Angeles
- University of California, Los Angeles - Los Angeles
- University of California, Davis - Martinez
- Stanford University - Palo Alto
- University of California, San Diego - San Diego
- University of California, San Francisco - San Francisco
Florida
- Mayo Clinic, Jacksonville - Jacksonville
- Wien Center - Miami Beach
- Premiere Research Institute - West Palm Beach
Arizona
- Banner Alzheimer's Institute - Phoenix
- Banner Sun Health Research Institute - Sun City
District of Columbia
- Georgetown University - Washington D.C.
- Howard University - Washington D.C.
Illinois
- Northwestern University - Chicago
- Rush University Medical Center - Chicago
Alabama
- University of Alabama at Birmingham - Birmingham
Connecticut
- Yale University School of Medicine - New Haven
Georgia
- Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 342 participants |
| Start Date | 2010-04 |
| Est. Completion | 2012-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01078636
The ClinicalTrials.gov registry entry for NCT01078636 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 342 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,269-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (73% lower). The listed sponsor is Alzheimer's Disease Cooperative Study (ADCS), which has 10 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Mild Cognitive Impairment appearing as the primary indexed condition, and to 0 interventions.
NCT01078636 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT01078636 about?
NCT01078636 is a clinical study titled "Alzheimer's Disease Neuroimaging Initiative Grand Opportunity". The purpose of this study is to build upon the information obtained in the original Alzheimer's Disease Neuroimaging Initiative (ADNI1), to examine how brain imaging technology can be used with other tests to measure the progression of mild cognitive impairment (MCI) and early Alzheimer's disease (A...
What is the current status of trial NCT01078636?
This trial is currently completed. The enrollment target is 342 participants. The study started on 2010-04. Estimated completion is 2012-10.
What conditions does trial NCT01078636 study?
This clinical trial studies the following conditions: Mild Cognitive Impairment, Alzheimers Disease.
Who is sponsoring clinical trial NCT01078636?
This trial is sponsored by Alzheimer's Disease Cooperative Study (ADCS), which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01078636 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mild Cognitive Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Wayfinding Intervention and Long-Term Memory
RECRUITING · NA
-
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
RECRUITING · Early Phase 1
-
MCI Speech in Noise
RECRUITING
-
Dual Task Perturbation Training for OAwMCI
RECRUITING · NA
-
Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY
RECRUITING
-
Effect of LEQEMBI on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer's Disease
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.